On the stock market since 2021, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
Sales run at $87.1M a year. A small number, but proof the product has real buyers.
A loss of $8.0M against $87.1M in annual sales.
Over the last 12 months, executives reported 6 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, VENA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VENA is a high-risk stock — not yet profitable, and its future rides on its product catching on.